Akebia Therapeutics, Inc. — fact timeline

Akebia Therapeutics, Inc. terminated Termination Agreement with BioVectra Inc. valued at $32,500,000 (effective 2022-12-22).

“On December 22, 2022, Keryx and BioVectra Inc. (“BioVectra”), entered into a termination and settlement agreement (the “Termination Agreement”). Pursuant to the Termination Agreement, Keryx and BioVectra agreed, among other things, to terminate, effective immediately, any and all existing agreements entered into between the parties in connection with the manufacture and supply, by BioVectra to the Company, of ferric citrate drug substance (the “Product”) for the Company’s proprietary product, Auryxia, including but not limited to that certain Manufacture and Supply Agreement, dated May 26, 2017, as amended by the Amendment to Manufacture and Supply Agreement, dated December 11, 2017 (the “Manufacture and Supply Agreement”), and that certain Amended and Restated Product Manufacture and Supply and Facility Construction Agreement, dated September 4, 2020 (the “Supply and Facility Construction Agreement”) (such agreements, collectively, the “BioVectra Agreements”). The parties agreed to te”

Akebia Therapeutics, Inc. entered into License Agreement with Averoa SAS (effective 2022-12-22).

“On December 22, 2022 (the “Effective Date”), Akebia Therapeutics, Inc. (the “Company”), Keryx Biopharmaceuticals, Inc., a wholly-owned subsidiary of the Company (“Keryx”), and Averoa SAS (“Averoa”) entered into a License Agreement (the “License Agreement”) pursuant to which the Company granted to Averoa an exclusive license to develop and commercialize ferric citrate”

David A. Spellman was appointed as principal accounting officer at Akebia Therapeutics, Inc..

“The Board of Directors of the Company has appointed David A. Spellman, the Company’s Chief Financial Officer, as principal accounting officer, effective as of the Effective Date.”

Violetta Cotreau resigned as Chief Accounting Officer at Akebia Therapeutics, Inc..

“On December 14, 2022, Violetta Cotreau, Chief Accounting Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of her intent to resign to pursue a new career opportunity.”

Akebia Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Extended Compliance Date, the Staff will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the Staff’s delisting determination to a Na”

Akebia Therapeutics, Inc. announced a restructuring with charges of approximately $1.8 million affecting commercial organization (approximately 14%).

“be offered separation benefits, including severance payments, healthcare coverage and related benefits. The Company expects to record a restructuring charge of approximately $1.8 million primarily related to one-time and contractual termination benefits including severance, non-cash stock-based compensation expense, healthcare and related benefits in the fourth”

Akebia Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $49.0 million.

“net price per pill puts us in a position to affirm our 2022 net product revenue guidance for Auryxia of $170 - $175 million.” Financial Results • Revenues: Total revenue was $49.0 million in the third quarter of 2022 compared to $48.8 million for the third quarter of 2021. • Net product revenue was $42.2 million in the third quarter of 2022 compared to $36.8”

Ron Frieson was elected as Class I director at Akebia Therapeutics, Inc..

“the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, increased the Board’s size from eight to nine directors and elected Ron Frieson as a Class I director.”